• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Immune alterations in malignant melanoma and current immunotherapy concepts
【24h】

Immune alterations in malignant melanoma and current immunotherapy concepts

机译：恶性黑色素瘤的免疫改变和当前的免疫治疗概念

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Malignant melanoma is a highly aggressive, immunogenic tumor that has the ability to modulate the immune system to its own advantage. Patients with melanoma present numerous cellular immune defects and cytokine abnormalities, all leading to suppression of the host anti-tumor immune response. Innovative treatment strategies can be achieved through employing our knowledge of the melanoma-induced immune alterations. Areas covered: The authors review comprehensively the immune abnormalities in individuals with melanoma, and provide a summary of currently available melanoma immunotherapy agents that are currently on the market or undergoing clinical trials. Expert opinion: Ipilimumab, a monoclonal antibody directed against the CTLA-4, is one of the current forefront treatment strategies in malignant melanoma. Novel immunomodulating agents have shown clear activity in patients with malignant melanoma. These include anti-PD-1 and anti-PD-1 ligand antibodies that may soon become important items in the anti-melanoma armamentarium. Combinations of different immunotherapy agents, between themselves or with other agents, are currently being studied in an attempt to further enhance the antineoplastic effect in patients with malignant melanoma.
机译：简介：恶性黑色素瘤是一种高度侵袭性的免疫原性肿瘤，具有调节免疫系统以发挥自身优势的能力。黑色素瘤患者表现出许多细胞免疫缺陷和细胞因子异常，所有这些都导致宿主抗肿瘤免疫反应受到抑制。通过运用我们对黑素瘤诱导的免疫改变的认识，可以实现创新的治疗策略。研究范围：作者全面审查了黑色素瘤患者的免疫异常情况，并提供了目前市场上或正在进行临床试验的当前可用的黑色素瘤免疫治疗剂的摘要。专家意见：伊匹木单抗是一种针对CTLA-4的单克隆抗体，是目前恶性黑色素瘤最重要的治疗策略之一。新型免疫调节剂在恶性黑色素瘤患者中显示出明显的活性。这些包括抗PD-1和抗PD-1配体抗体，它们可能很快会成为抗黑素瘤武器库中的重要项目。目前正在研究不同免疫治疗剂之间或与其他治疗剂的组合，以进一步增强恶性黑色素瘤患者的抗肿瘤作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号